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Introduction 
Malaria is a parasitic disease that infiltrates red blood cells and is caused by 
microorganisms of the Plasmodium genus1.  The name malaria (from Italian) stems from a 
proposed causative role of “bad air” from marshy environments as being responsible for 
infection1.   It was not until 1880, that the French physician Alphonse Laveran isolated 
organisms from within red blood cells found to be uniquely present in those infected with 
malaria.  He determined that these isolated organisms were intracellular parasites of the 
Plasmodium species and, a few years later, Sir Ronald Ross isolated Plasmodia from 
Anopheles mosquito stomach tissue, indicating a possible vector for malarial transmission1.  
Malaria is by far the world’s most common cause of parasitic morbidity and mortality. In the year 
2017, approximately 219 million global cases of malaria occurred along with 435,000 deaths 
caused by infection. Malaria is a parasitic disease of red blood cells caused by microorganisms of 
the Plasmodium species usually contracted and spread by the female Anopheles mosquito: typical 
symptoms include headache, vomiting, and fever with more serious manifestations resulting in 
jaundice, seizures, coma and even death. While malarial infection is usually non-fatal, some types 
are implicated in chronic recurrence, vascular occlusion, and diminished oxygen transport 
(hypoxia). The type and severity of malarial infection is predicated upon the species of parasite, 
with each of four types possessing different characteristics and distinct impacts on pathogenesis 
and mortality. Treatment primarily involves pharmaceuticals targeting various stages of the 
Plasmodium life cycle by either killing the parasite or preventing its replication. Prevention 
involves protection from mosquitoes with netting and the recent completion of clinical trials on the 
first anti-malarial vaccine to be approved by the WHO in 2015. In addition, high-risk populations 
in historically tropical areas may possess genetic alterations that facilitate resistance to the malarial 
disease process of which the biochemical consequences of Sickle Cell Disease as well as a 
condition known as Glucose 6-Phosphate Dehydrogenase Deficiency will be discussed. This 
review concerns the specific challenges associated with current malarial treatment as well as 
current efforts to produce a lasting viable alternative to current disease management.  
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Malaria remains the most common global cause of parasitic morbidity and mortality.  In 2017, 
approximately 219 million global cases of malaria occurred along with 435,000 total deaths 
caused by this parasitic infection2.  
 
 
Figure 1: Malaria has remained consistent as a leading cause of early death3 
 
Malaria is well-known for its recurrent fevers that cyclically wax and wane depending 
upon parasite life-cycle stage in those infected.  Fever onset typically aligns with the lysis of 
red blood cells and generally declines in intensity until the next round of hemolysis occurs.  
Far from a newly discovered phenomenon, Hippocrates, “The Father of Medicine”, is 
believed to have differentiated the intermittent fevers of malaria from those of other febrile 
illnesses and denoted the periodicity of infection in 400 BC4.  Many symptoms from malarial 
infection are variable as well as non-specific and include headache, weakness, abdominal 
pain, and vomiting4.   
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Creative Challenge: How are biochemical and physiological systems affected by Plasmodium 
pathogenesis?  What efforts are taken to reduce the impact of malarial transmission and what 
novel techniques are being implicated in mitigating disease?        
 
Malaria Types and Pathogenesis    
The “type” of malarial infection that occurs is determined by the species of parasite, 
each possessing different characteristics that uniquely impact pathogenesis and influence 
mortality.  Malaria in humans is acquired from four species of Plasmodium: P. falciparum, P. 
malariae, P. ovale, and P. vivax4.  P. falciparum is the species that causes the most severe 
complications associated with malaria and is responsible for nearly all malarial mortalities.  
These severe complications may include pulmonary edema, cerebral malaria, acute renal 
(kidney) failure, acidosis, hypoglycemia, anemia, and bleeding4,5. 
 
Figure 2: Life-cycle of plasmodium species implicated in malaria13  
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Malarial infection is typically categorized by two major stages: erythrocytic and 
exoerythrocytic stages5.  The exoerythrocytic stage refers to parasitic infiltration into sites 
such as the liver while erythrocytic stage concerns accumulation and completion of life-cycle 
within circulating red blood cells.  Initial infection occurs when an infected female anopheles 
mosquito feeds on human blood and releases immature plasmodium called sporozoites into 
the host circulation5.  These sporozoites enter the liver where they grow and mature into 
schizonts and later merozoites.  Merozoites are released into the blood stream where they 
encounter red blood cells (RBC)5.  Upon cell invasion, these plasmodia develop ring-shaped 
structures within the RBC, an essential diagnostic marker to determine malaria infection.  
While infection in the blood is often readily apparent, Plasmodia within the liver remain 
relatively undetectable as patients are asymptomatic and diagnostics are generally based on 
blood smears. Although all species of Plasmodium transition to the liver immediately upon 
host introduction, P. vivax and P. ovale can exist within the liver in a dormant stage, evading 




While species such as P. vivax and P. malariae are restricted to invading young and 
old red blood cells respectively, P. falciparum can invade any red blood cell regardless of age; 
thus, very high levels of the parasite can be found in blood (parasitemia)6.   One of the 
distinctive characteristics of P. Falciparum is a consequence of its’ more effective host 
incorporation as well as its’ possessing a unique protein called Plasmodium falciparum 
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erythrocyte membrane protein 1 (PfEMP1) that can lead to vascular occlusion.  PfEMP1 is 
expressed by mature erythrocytic parasites and is anchored to knobs found upon the surface of 
the infected red blood cell (iRBC)7.  Once attached to the red blood cell surface, PfEMP1 can 
mediate connections with either uninfected red blood cells or endothelial tissue aptly known 
as cytoadhesion.  This adhesion allows the iRBC to sequester within tissues, allowing the 
parasite to complete its life-cycle without being eliminated by the spleen.  Increased 
cytoadhesion with vascular walls may also occlude blood flow, resulting in diminished 
oxygen transport to tissues and thus tissue death and necrosis7.   
This inadequate blood perfusion may also lead to a severe loss in oxygen and glucose 
assimilation critical to tissue such as brain8.  Despite the prevalence of parasites within the 
brain, many brain related complications, including coma and epilepsy, can often be reversed 
with treatment and reveal little long-standing tissue necrosis.  One proposed mechanism for 
the reversibility of neurological issues comes from the theory that certain chemicals are 
responsible for interference with neurotransmission8.  It has been suggested that nitric oxide 
(NO), a byproduct of host defense signaling, can readily cross the blood brain barrier and 
negatively impact brain signaling.  Once this chemical is no longer present, as in the case of 
malarial clearance, the negative impacts to the brain signaling cascade no longer occur.  Other 
metabolites produced by infection such as Quinolinic acid are also suspected to be implicated 
in seizures related to malarial infection8.     
 
Laboratory Diagnostics 
 All plasmodium species share a common ring structure within red blood cells, as seen 
on microscopy, and are thus often difficult to differentiate by physical attributes alone9.  A 
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few key characteristics of the ring structure, of the parasite within the red blood cell, exist that 
can help enable the differentiation of species.  The ring structure of P. falciparum is often 
identified as having delicate cytoplasm and small chromatin dots whereas the other Plasmodia 
species demonstrate sturdy cytoplasm with large chromatin content when examined 
microscopically.  P. malariae and P. ovale are virtually indistinguishable save for P. ovale 
containing Schuffner’s dots and P. malariae often having Ziemann’s stippling.  Schuffner 
dots are generally smooth and brown in color, while Ziemann granules are coarse and black.  
Red blood cells which contain P. vivax are generally seen as much larger than cells containing 
other plasmodium species9.  Characteristics of both the parasite and its host cell differ 
depending on life-cycle stage.  Due to extensive similarity, accurate species diagnosis may 
prove difficult by morphology alone and distinctions based on physical illness may be 
required to determine exact species identity9.   
 
 
Figure 3: Representative images of life stages of infectious Plasmodia9 
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 Samples are prepared by obtaining blood smears from peripheral areas of the patient 
such as a fingertip.  The blood is allowed to dry on a slide and then subjected to Giemsa 
staining, a stain limited to phosphate groups of DNA.  Mature red blood cells do not contain 
DNA; thus, the stain proves a selective diagnostic marker for identifying plasmodium species.  
While Giemsa staining has long been the “gold standard” for malaria diagnosis and still 
remains the first-step in identification, a technique known as Polymerase Chain Reaction 
(PCR) is a more sensitive and objective diagnostic tool.  An amplification of the 18S rRNA 
gene in each isolated parasite reveals a different segment length specific to each species, 
providing a means of genetic differentiation on the basis of fragment size10.  When combined 
with light-microscopy identification, the PCR method provides an attractive addition to 
current disease identification and aides in treatment selection.  A current limitation with this 
technology remains its cost as well as the need for skilled technicians.  Thus, in areas where 
malaria is endemic, there are some impediments to its use and overall success10.    
 
Chemoprophylaxis 
 An early malarial remedy successfully used in Latin America for hundreds of years 
was to chew the bark of a cinchona tree.  This appeared to be both a protective and a 
therapeutic measure against infection by the indiginous people11.  Centuries later, the 
chemical agent responsible for parasitic prevention in the cinchona bark was isolated by the 
British and identified as Quinine (Gin and Tonic).  Quinine is effective against intra-
erythrocytic plasmodium and gametocytocidal for most malaria parasites; however, its’ 
specific anti-malarial mechanism is still unknown.  While Quinine and its derivatives remain 
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relevant in malarial treatment, synthetic anti-malarials such as chloroquine have taken 
precedence in clinical use11.  Despite the beneficial impact that chloroquine has had on 
managing infections, global resistance to chloroquine treatment has sharply risen within the 
last century, particularly in South America and South-East Asia.  Plasmodium falciparum in 
particular has demonstrated remarkable abilities to adapt in becoming resistant to medication 
use with it also developing resistance to newer pharmaceuticals such as Artemisinin as well.    
 
 
Figure 4: Development of global P. falciparum resistance to malaria12 
 
 Many medicines induce resistance within their targets by vastly increasing the 
proportion of resistant to non-resistant strains.  These resistant strains thus experience less 
growth competition and are able to persist when non-resistant parasites are eliminated13.  The 
spread of resistance from host to greater population is difficult for Plasmodium due as they 
must successfully produce three-unlikely events.  First, the parasite must develop changes in 
its genome, which facilitate a resistance to the pharmaceutical.  Second, the Plasmodium must 
survive host defenses long enough to produce gametocytes, the reproductive cells of 
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Plasmodium.  Third, the host must experience an event, such as a mosquito bite or blood 
transfusion, that enables transfer to another organism13.  Another interesting phenomenon is 
that resistance spread is attenuated with introduction of the organism to an untreated host.  
This is partly due to increased competition with non-resistant strains, therefore limiting 
proliferation and the production of gametocytes. 
The anti-malarial Artemisinin shares a common history with Quinine as an herbal 
remedy for plasmodium infection.  The theory of Artemisinin’s protective qualities came from 
a Chinese analysis and screening of hundreds of folk medicines sharing this common 
ingredient14.  In vitro studies of Plasmodium falciparum subjected to Artemisinin treatment, 
revealed a significant inhibition on activity.  Artemisinin is suggested to produce its anti-
malarial effect by forming radicals through its peroxide bond.  Parasitic consumption of 
hemoglobin is implicated in iron release, which interacts with artemisinin’s bond to produce 
toxic oxygen species that damage red blood cell membranes15. These red blood cells are prone 
to apoptosis as well as rapid clearance from circulation.     
The plasmodia species has a distinct life-cycle progression: schizont to merozoite to 
trophozoite. A schizont is the obligate intracellular Plasmodium form, which causes rupture of 
host cell and release as a merozoite5. Merozoites, the free form of plasmodium within the 
blood stream, can enter RBCs where they develop into trophozoites5.   Response to 
medication largely depends upon the specific stage the Plasmodium occupies with different 
sensitivity related to different tissues.  Many current medications are derivatives of quinine 
and include quinidine, primaquine, mefloquine, and chloroquine.  These artificial compounds 
all share a nitrogen containing aromatic ring, but there are differences in identity of the groups 
appended to these rings.   
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Figure 5: Anti-malarials and their respective targets28 
 
The hypnozoite stage is of immense clinical importance as it only exists in P. vivax 
and P. ovale infections, the species that can remain dormant within the liver.  The drug of 
choice for these infections is primaquine, a drug that specifically attacks the latent parasitic 
organism16.  A typical treatment course involves primaquine supplementation coupled with a 
schizonticide to prevent possible relapse following care.  
Primaquine, also used in P. falciparum treatment, is not associated with liver damage 
and no serious instances of adverse drug reaction under normal dosages are known to occur.  
Complications may arise if primaquine is given to those with glucose-6-phosphate 
dehydrogenase deficiency as hemolytic anemia may occur.  Thus, the use of primquine is 
contraindicated in patients that have G6PD deficiency16.     
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Folate is a nutrient that serves an essential role in the synthesis, replication, and repair of 
DNA.  If folate levels are low, protozoa such as Plasmodium will cease to replicate.  
Sulfonamides, often referred to as sulfa drugs, are a broad class of antibiotics that can 
attenuate folate synthesis within parasites17.  The method of sulfonamides’ folate inhibition is 
related to mimicry of PABA, an intermediate in folate synthesis.  While PABA undergoes 
further metabolism, enzymes that recognize PABA can bind sulfonamides but produce no 
active metabolites.  Sulfa drugs are well-known for their variety of side-effects, which often 
include allergy and abnormal hemoglobin synthesis; however, they remain a promising and 
reasonable alternative to quinine derivations in light of increasing chloroquine resistance17.  
 
Vaccination  
While chemoprophylaxis is a viable means of disease management, inherent 
disadvantages exist as it is a therapeutic rather than preventative measure in most cases.  The 
costs and resources associated with treating malarial infections far exceed those of an 
effective vaccine.  Vaccines introduce pathogenic material to a subject in a controlled manner, 
which does not produce symptoms of typical infection29.  The subject recognizes this 
substance as foreign and the body begins to develop immune responses concerned with 
removing the infection, leading to immunity29.       
In the 1960s, the injection of plasmodia attenuated by radioactive treatment revealed a 
protective effect from later parasitic infection18.  Later, of the numerous potential candidate 
proteins to establish effective vaccination, the circumsporozoite protein (CSP) was selected as 
a possible inductor of immune response, and the gene encoding this surface protein was 
identified18.  CSP was chosen in part due to its surface expression on pre-erthyocytic 
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sporozoites as well as upon infected hepatocytes.  Thus, the immune system is induced to 
recognize plasmodia before symptoms manifest as a result of erythrocyte infiltration.    
Vaccines composed of CSP constructs initially yielded no substantial protective 
benefit however, later coupled with an alternative protein from a Hepatitis B virus; this hybrid 
vaccine was developed under the name RTS,S18. 
 
Figure 6: RTS,S is associated with reductions in overall disease and severe disease19 
 
The results of multiple vaccine trials indicate that, while this vaccine is reasonably 
effective, immunity tends to decrease over time and is largely dependent on the number of 
booster shots received.  This suggests vaccination would be best coordinated with birth or 




Genetic resistance to malaria 
Unique environmental pressures can select for desirable traits as well as mutations if 
they enable greater viability for an organism.  Populations who live, or have historically lived, 
within tropical and sub-tropical areas rich in malaria show a much greater incidence of genetic 
alterations which produce a protective effect against infection.  Two of the most prevalent 
biochemical/genetic alterations compromise the stability of Red Blood Cells under stress: 
Sickle Cell Disease and Glucose 6-Phosphate Dehydrogenase Deficiency.     
Glucose 6-Phosphate Dehydrogenase (G6PD) is a metabolic enzyme that facilitates 
the generation of glutathione, a protective antioxidant responsible for sequestering harmful 
compounds known as reactive oxygen species22.  Malaria introduces hydroxyl radicals within 
RBCs that create oxidative stress.  In individuals with normal G6PD, glutathione can mitigate 
this stress on the RBC cell wall; however, if an individual is deficient in G6PD, this 
unattenuated oxidative build-up can facilitate a bursting (hemolysis) of infected cells when 
exposed to further stress such as Plasmodium infection22.  A destruction of red blood cells 
containing plasmodium destroys the parasite along with the erythrocyte.  Thus, hemolysis is a 
protective outcome of parasitic infiltration.  In regions where malaria is not prevalent or in 
high altitude environments that cause elevated levels of oxidative stress, G6PD deficiency 
tends to be a harmful trait as it increases the fragility of red blood cells and causes hemolysis 
along with disease processes associated with this.       
       
 Sickle Cell Disease has similar effects to G6PD Deficiency in its abetment of RBC 
removal, but the cause of this increased toxicity differs.  In Sickle Cell Disease, RBC lysis is 
accelerated by an atypical hemoglobin morphology rather than the concentration of a 
 15 
biochemical product23.  Normal red blood cells have a smooth rounded shape but sickle cells 
present with an abnormal semi-lunar distortion.  The sickle shape is not omnipresent, but 
manifests only under specific conditions.  When oxygen is bound to hemoglobin, the mutated 
valine is prevented from interacting with residues necessary for altering shape; however, 
when oxygen is not bound to hemoglobin, interacting residues are left exposed, which cause 
negative modifications to RBC architecture23.   Plasmodium infection is thought to interfere 
with successful oxygen binding to hemoglobin, thus helping to initiate the sickle shape.  
These sickled cells, containing parasitic organisms are then rapidly removed from the 
circulation by the spleen and other organs. 
 
 




An Ounce of Prevention 
 Preventative measures such as the use of mosquito bed netting have been met with 
demonstrable success.  A series of 23 experimental trials indicated that the use of insecticide-
 16 
treated nets when compared to no net use was responsible for reducing child mortality by 17% 
with a 44% reduction in cases of severe malaria25.  However, net acquisition does not 
necessarily denote compliance, as many recipients report using their nets for alternative 
purposes and thus, some level of educational reform may be helpful/necessary to impact 
public awareness25.   
Successful spread of malaria depends on many factors which include a mosquito 
lifetime, access to blood meal, and range of distribution.  Due to all the potential impediments 
to transmission, Sir Ronald Ross accurately determined that in order to eliminate malarial 
infection one did not have to eradicate the entire Anopheles population, but only reduce 
mosquito number to a critical threshold13.  This idea formed the large-scale eradication 
movement in the 1950s, which resulted in the large-scale use of insecticides.  This application 
showed tremendous success in regions such as South Asia, but the efforts ultimately failed 
due to deficient funding as well as rising concerns about the safety of many of the pesticides 
in use13.   
DDT has also been used extensively in the latter half of the 20th century as a very 
effective insecticide for mosquitos; however, it’s use expanded greatly to other insects and 
was heavily used in agriculture before becoming restricted in recent years due to a variety of 
concerns26.  The most concerning effect of DDT is its implications in both teratogenicity and 
carcinogenicity as well as its’ environmental toxicity, which include damage to surrounding 
foliage as well as non-specific effects on innocuous insects, and wildlife26.  Rachel Carson, in 
her influential book Silent Spring, famously targeted DDT as an agent that caused irrevocable 
harm to nature, arguing for its elimination. Newer pesticides have since been more tightly 
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regulated in their production and their use, and few have shown efficacy at mosquito 
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